Related to this topic: Support | UK Guidelines | Weblinks | Equipment | Books | Your Experience | Other resources | Glossaries
Print options:
Other options:
(what's this?)
PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.
Churg-Strauss Syndrome
Synonyms: allergic granulomatosis angiitis, granulomatous small-vessel vasculitis
A rare diffuse vasculitic disease affecting coronary, pulmonary, cerebral, abdominal visceral and skin circulations. The vasculitis affects small and medium sized arteries and veins and is associated with asthma. The aetiology is unknown.1
- Incidence is approximately 2.5 cases per 100,000 adults per year
- Males are affected slightly more frequently than females
- The age at onset varies from 15-70 years
The physical findings are specific to organ system involvement. There are three phases:
- Allergic rhinitis and asthma
- Eosinophilic infiltrative disease, such as eosinophilic pneumonia or gastroenteritis
- Systemic medium- and small-vessel vasculitis with granulomatous inflammation
The vasculitic phase usually develops within 3 years of the onset of asthma, although it may be delayed for several decades. The most prominent symptoms and signs are:
- Pulmonary: asthma, pneumonitis and haemoptysis
- Upper respiratory tract: allergic rhinitis, paranasal sinusitis, nasal polyposis
- Cardiac: heart failure, myocarditis, and myocardial infarction
- Skin: purpura, skin nodules, leukocytoclastic angiitis with palpable purpura, livedo reticularis, urticaria, necrotic bullae and digital ischaemia
- Renal: glomerulonephritis, hypertension and advanced renal failure
- Peripheral neuropathy: mononeuritis multiplex (most frequent form, occurring in as many as 77% of patients). Less frequent symptoms include stroke and eye involvement.
- Gastrointestinal: vasculitis and bleeding, bowel ischaemia and perforation, appendicitis and pancreatitis
- Malaise, fatigue, weight loss, fever, myalgia and arthralgia
- Other causes of systemic vasculitis:2
- Primary vasculitis, e.g. polyarteritis nodosa, Wegener granulomatous
- Secondary vasculitis: a complication of a connective tissue disorder (e.g. rheumatoid arthritis), infection, medication, or malignancy.
- Wegener granulomatosis and microscopic polyangiitis are also vasculitic syndromes involving small and medium-sized vessels that are associated with antibodies to neutrophil cytoplasmic antigens.
- Antineutrophil cytoplasmic antibodies: 70% of patients are perinuclear-ANCA (p-ANCA) positive (antimyeloperoxidase antibodies).
- Other likely finding include full blood count shows eosinophilia and anaemia; elevated ESR and CRP; elevated serum creatinine; increased serum IgE levels, hypergammaglobulinaemia; proteinuria, microscopic haematuria, and red blood cell casts in the urine.
- Chest x-ray: pulmonary opacities, transient pulmonary infiltrates, pleural effusions.
- Pulmonary CT scan: peripheral areas of parenchymal consolidation with ground-glass attenuation similar to chronic eosinophilic pneumonia.
- Biopsy: The characteristic changes, found especially in the lung, include small necrotizing granulomas, as well as necrotizing vasculitis involving small arteries and venules.
- Other investigations are indicated for the complications of the disease and specific organ system involvement.
- High dose steroids are usually adequate for treatment.
- Cyclophosphamide is administered in patients with severe or life-threatening complications. Azathioprine is also used.
- Other treatments include intravenous immune globulin, interferon-alpha, and plasma exchange.
- Complications of vasculitis depend on the specific organ system involvement.
- The principal causes of morbidity and mortality are myocarditis and myocardial infarction secondary to coronary arteritis.
- Although the overall prognosis is good, and treatment with prednisone alone or in combination with immunosuppressive drugs is usually successful, severe asthma typically persists.3
- Diffuse organ involvement of Churg-Strauss syndrome, especially cardiovascular and rare involvement of the CNS and renal system, suggests a poorer prognosis and can be fatal.3
- Without treatment, the 5-year survival rate is about 25%.
- With treatment, the 1-year survival rate is 90% and the 5-year survival rate is 62%.
- Although treatment regimes are often successful, severe asthma usually persists.
Document References
- Farid-Moayer M; Churg-Strauss Syndrome. eMedicine, January 2007.
- Gorson KC; Vasculitic neuropathies: an update. Neurologist. 2007 Jan;13(1):12-9. [abstract]
- Noth I, Strek ME, Leff AR; Churg-Strauss syndrome. Lancet. 2003 Feb 15;361(9357):587-94. [abstract]
Internet and Further Reading Acknowledgements EMIS is grateful to Dr Colin Tidy for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2007.
DocID: 1962
Document Version: 20
DocRef: bgp24815
Last Updated: 30 Apr 2007
Review Date: 29 Apr 2009
Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.
Related pages in Patient UK
Your Experience (^ top of page)
Please add your experience about this condition / medicinePatient Support related to this topic (^ top of page)
Vasculitis Support Group West MidlandsUK guidelines related to this topic (^ top of page)
Guidelines on Churg-strauss SyndromeLinks to other selected websites related to this topic (^ top of page)
Churg - Strauss SyndromeOther - Useful resources (^ top of page)
Pictures, diagrams, photos, images, etc.Evidence based medicine
Online textbooks and journals
A-Z of UK Guidelines
A-Z of Online Videos
Medline
Other good health sites
Medical equipment products related to this topic (^ top of page)

Books related to this topic (^ top of page)

Want to search some more? Use the Google Search box below to search our site.

Would you like to try our advanced on-line knowledge support system designed to provide professionals with relevant up to date information about recognition and management of disease or take the Mentor Challenge?

